Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion

Authors: Hamada, Akira, Suda, Kenichi, Nishino, Masaya, Obata, Keiko, Oiki, Hana, Fukami, Tomoyo, Fukuda, Shota, Fujino, Toshio, Ohara, Shuta, Koga, Takamasa, Chiba, Masato, Shimoji, Masaki, Ito, Masaoki, Takemoto, Toshiki, Soh, Junichi, Tsutani, Yasuhiro, Mitsudomi, Tetsuya

Source: In Journal of Thoracic Oncology January 2024 19(1):71-79

Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing

Authors: Koga, Takamasa, Soh, Junichi, Hamada, Akira, Miyano, Yuki, Fujino, Toshio, Obata, Keiko, Ohara, Shuta, Nishino, Masaya, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Suda, Kenichi, Sakai, Kazuko, Sato, Hidenori, Mitsudomi, Tetsuya

Source: In JTO Clinical and Research Reports September 2023 4(9)

Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas

Authors: Fujino, Toshio, Suda, Kenichi, Sakai, Kazuko, Murakami, Isao, Shimizu, Shigeki, Ohara, Shuta, Koga, Takamasa, Hamada, Akira, Soh, Junichi, Nishio, Kazuto, Mitsudomi, Tetsuya

Source: Clinical lung cancer. 23(3):e185-e195

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100162457740.0x000001&indx=1&recIds=ETOCvdc_100162457740.0x000001

Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer

Authors: Suda, Kenichi, Ohara, Shuta, Fujino, Toshio, Hamada, Akira, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Soh, Junichi, Mitsudomi, Tetsuya

Source: Clinical lung cancer. 23(1):e60-e68

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100153309095.0x000001&indx=1&recIds=ETOCvdc_100153309095.0x000001

GUK1 activation is a metabolic liability in lung cancer.

Authors: Schneider, Jaime L.^1,2, jschneider@mgh.harvard.edu, Kurmi, Kiran¹, Dai, Yutong^1,3, Dhiman, Ishita¹, Joshi, Shakchhi¹, Gassaway, Brandon M.¹, Johnson, Christian W.^1,4, Jones, Nicole¹, Li, Zongyu¹, Joschko, Christian P.¹, Fujino, Toshio², Paulo, Joao A.¹, Yoda, Satoshi^1,2, Baquer, Gerard⁵, Ruiz, Daniela^1,5, Stopka, Sylwia A.⁵, Kelley, Liam¹, Do, Andrew², Mino-Kenudson, Mari⁶, Sequist, Lecia V.²

Source: Cell; Mar2025, Vol. 188 Issue 5, p1248-12126, 10879p

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC

Authors: Hamada, Akira, Suda, Kenichi, Fujino, Toshio, Nishino, Masaya, Ohara, Shuta, Koga, Takamasa, Kabasawa, Takanobu, Chiba, Masato, Shimoji, Masaki, Endoh, Makoto, Takemoto, Toshiki, Soh, Junichi, Yanagawa, Naoki, Shiono, Satoshi, Mitsudomi, Tetsuya

Source: In JTO Clinical and Research Reports May 2022 3(5)

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial

Authors: Hamada, Akira, Suda, Kenichi, Koga, Takamasa, Fujino, Toshio, Nishino, Masaya, Ohara, Shuta, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Soh, Junichi, Uchida, Tetsuro, Mitsudomi, Tetsuya

Source: In Lung Cancer December 2021 162:79-85

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

Authors: Koga, Takamasa, Suda, Kenichi, Fujino, Toshio, Ohara, Shuta, Hamada, Akira, Nishino, Masaya, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Arita, Takeo, Gmachl, Michael, Hofmann, Marco H., Soh, Junichi, Mitsudomi, Tetsuya

Source: In Journal of Thoracic Oncology August 2021 16(8):1321-1332

Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer

Authors: Ohara, Shuta, Suda, Kenichi ^*, Fujino, Toshio, Hamada, Akira, Koga, Takamasa, Nishino, Masaya, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Soh, Junichi, Mitsudomi, Tetsuya

Source: In Lung Cancer April 2021 154:84-91

Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non–Small Cell Lung Cancers: Analysis of Five Cases

Authors: Suda, Kenichi, Sakai, Kazuko, Obata, Keiko, Ohara, Shuta, Fujino, Toshio, Koga, Takamasa, Hamada, Akira, Soh, Junichi, Nishio, Kazuto, Mitsudomi, Tetsuya

Source: In Clinical Lung Cancer March 2021 22(2):e141-e145

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance

Authors: Nishino, Masaya, Suda, Kenichi, Koga, Takamasa, Ohara, Shuta, Fujino, Toshio, Soh, Junichi, Tirunagaru, Vijaya, Vellanki, Avanish, Doebele, Robert C., Mitsudomi, Tetsuya

Source: Thoracic cancer. 12(10):1511-1516

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100120687246.0x000001&indx=1&recIds=ETOCvdc_100120687246.0x000001

Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer

Authors: Suda, Kenichi, Murakami, Isao, Obata, Keiko, Sakai, Kazuko, Fujino, Toshio, Koga, Takamasa, Ohara, Shuta, Hamada, Akira, Soh, Junichi, Nishio, Kazuto, Mitsudomi, Tetsuya ^*

Source: In Lung Cancer October 2020 148:100-104

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Authors: Fujino, Toshio, Kobayashi, Yoshihisa, Suda, Kenichi, Koga, Takamasa, Nishino, Masaya, Ohara, Shuta, Chiba, Masato, Shimoji, Masaki, Tomizawa, Kenji, Takemoto, Toshiki, Mitsudomi, Tetsuya

Source: In Journal of Thoracic Oncology October 2019 14(10):1753-1765

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

Authors: Fujino, Toshio, Suda, Kenichi, Mitsudomi, Tetsuya

Source: Expert opinion on emerging drugs. 25(3):229-249

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100110699810.0x000001&indx=1&recIds=ETOCvdc_100110699810.0x000001

Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro

Authors: Nishino, Masaya, Suda, Kenichi, Kobayashi, Yoshihisa, Ohara, Shuta, Fujino, Toshio, Koga, Takamasa, Chiba, Masato, Shimoji, Masaki, Tomizawa, Kenji, Takemoto, Toshiki, Mitsudomi, Tetsuya

Source: In Lung Cancer December 2018 126:149-155

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study

Authors: Koga, Takamasa, Kobayashi, Yoshihisa, Tomizawa, Kenji, Suda, Kenichi, Kosaka, Takayuki, Sesumi, Yuichi, Fujino, Toshio, Nishino, Masaya, Ohara, Shuta, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Suzuki, Makoto, Jänne, Pasi A., Mitsudomi, Tetsuya

Source: In Lung Cancer December 2018 126:72-79

Micronodular thymoma with lymphoid stroma diagnosed 10 years after the first operation: a case report

Authors: Kaminuma, Yasunori, Tanahashi, Masayuki, Yukiue, Haruhiro, Suzuki, Eriko, Yoshii, Naoko, Fujino, Toshio, Ogawa, Hiroshi, Niwa, Hiroshi

Source: Journal of medical case reports. 13(1):1-4

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100186546379.0x000001&indx=1&recIds=ETOCvdc_100186546379.0x000001

Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis

Authors: Tomizawa, Kenji, Sato, Katsuaki, Ohara, Shuta, Fujino, Toshio, Koga, Takamasa, Nishino, Masaya, Kobayashi, Yoshihisa, Chiba, Masato, Shimoji, Masaki, Suda, Kenichi, Takemoto, Toshiki, Mitsudomi, Tetsuya

Source: Surgery today. 49(6):513-520

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100125381669.0x000001&indx=1&recIds=ETOCvdc_100125381669.0x000001

Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer

Authors: Tomizawa, Kenji, Shimizu, Shigeki, Ohara, Shuta, Fujino, Toshio, Nishino, Masaya, Sesumi, Yuichi, Kobayashi, Yoshihisa, Sato, Katsuaki, Chiba, Masato, Shimoji, Masaki, Suda, Kenichi, Takemoto, Toshiki, Mitsudomi, Tetsuya

Source: In Lung Cancer October 2017 112:57-61

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.

Authors: Fujino, Toshio¹ (AUTHOR), Suda, Kenichi¹ (AUTHOR), Koga, Takamasa¹ (AUTHOR), Hamada, Akira¹ (AUTHOR), Ohara, Shuta¹ (AUTHOR), Chiba, Masato¹ (AUTHOR), Shimoji, Masaki¹ (AUTHOR), Takemoto, Toshiki¹ (AUTHOR), Soh, Junichi¹ (AUTHOR), Mitsudomi, Tetsuya¹ (AUTHOR) mitsudom@med.kindai.ac.jp

Source: Journal of Hematology & Oncology. 6/11/2022, Vol. 15 Issue 1, p1-14. 14p.

Subject Terms: *NON-small-cell lung carcinoma, *GENETIC mutation, *EPIDERMAL growth factor receptors, *TREATMENT failure, *MOLECULAR dynamics